Celltrion’s IND Application for CT-P55 was Approved by the PDMA to Initiate a P-I Clinical Trial for the Treatment of Psoriasis
Shots:
- Following the IND approval, the company will initiate a P-I clinical trial evaluating CT-P55 in vs Cosentyx in patients (n=171) with psoriasis. The study will evaluate the PK equivalence between CT-P55 and Cosentyx (US & EU sourced)
- Moreover, the company expects to expand its autoimmune portfolio from tumor necrosis factor-alpha (TNF-alpha) inhibitors to interleukin inhibitors
- Cosentyx is an IL-17A inhibitor developed by Novartis for the treatment of psoriatic arthritis, ankylosing spondylitis & moderate-to-severe plaque psoriasis. Cosentyx’s patent expires in Jan 2029 in the US & in Jan 2030 in Europe
Ref: BusinessKorea | Image: Celltrion
Related News:- Celltrion Launches Yuflyma (biosimilar, adalimumab) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
